12 Aptamers for the Diagnosis and Therapy …
369
12. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R (2010) Applications of aptamers in
nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine 5(9):1435–
1445. https://doi.org/10.2217/nnm.10.115
13. Zou X, Wu J, Gu J, Shen L, Mao L (2019) Application of aptamers in virus detection and
antiviral therapy. Front Microbiology 10:1462. https://doi.org/10.3389/fmicb.2019.01462
14. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA
ligands to bacteriophage T4 DNA polymerase. Science 249(4968):505–510. https://doi.org/
10.1126/science.2200121
15. Ali MH, Elsherbiny ME, Emara M (2019) Updates on aptamer research. Int J Mol Sci 20(10).
https://doi.org/10.3390/ijms20102511
16. Yan J, Xiong H, Cai S, Wen N, He Q, Liu Y, Peng D, Liu Z (2019) Advances in aptamer
screening technologies. Talanta 200:124–144. https://doi.org/10.1016/j.talanta.2019.03.015
17. Wang T, Chen C, Larcher LM, Barrero RA, Veedu RN (2019) Three decades of nucleic acid
aptamer technologies: lessons learned, progress and opportunities on aptamer development.
Biotechnol Adv 37(1):28–50. https://doi.org/10.1016/j.biotechadv.2018.11.001
18. Zhang Y, Lai BS, Juhas M (2019) Recent advances in aptamer discovery and applications.
Molecules 24(5). https://doi.org/10.3390/molecules24050941
19. Bauer M, Strom M, Hammond DS, Shigdar S (2019) Anything you can do, i can do better:
can aptamers replace antibodies in clinical diagnostic applications? Molecules 24(23). https://
doi.org/10.3390/molecules24234377
20. Toh SY, Citartan M, Gopinath SC, Tang TH (2015) Aptamers as a replacement for antibodies
in enzyme-linked immunosorbent assay. Biosens Bioelectron 64:392–403. https://doi.org/10.
1016/j.bios.2014.09.026
21. Zamay TN, Zamay GS, Shnayder NA, Dmitrenko DV, Zamay SS, Yushchenko V, Kolovskaya
OS, Susevski V, Berezovski MV, Kichkailo AS (2020) Nucleic acid aptamers for molecular
therapy of epilepsy and blood-brain barrier damages. Mol Ther Nucl Acids 19:157–167.
https://doi.org/10.1016/j.omtn.2019.10.042
22. Yazdian-Robati R, Bayat P, Oroojalian F, Zargari M, Ramezani M, Taghdisi SM, Abnous K
(2019) Therapeutic applications of AS1411 aptamer, an update review. Int J Biol Macromol.
https://doi.org/10.1016/j.ijbiomac.2019.11.118
23. Panigaj M, Johnson MB, Ke W, McMillan J, Goncharova EA, Chandler M, Afonin KA (2019)
Aptamers as modular components of therapeutic nucleic acid nanotechnology. ACS Nano.
https://doi.org/10.1021/acsnano.9b06522
24. Nuzzo S, Roscigno G, Affinito A, Ingenito F, Quintavalle C, Condorelli G (2019) Potential
and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision
medicine in cancer. Cancers 11(10). https://doi.org/10.3390/cancers11101521
25. Maimaitiyiming Y, Hong F, Yang C, Naranmandura H (2019) Novel insights into the role of
aptamers in the fight against cancer. J Cancer Res Clin Oncol 145(4):797–810. https://doi.
org/10.1007/s00432-019-02882-7
26. Li W, Zhao M, Yan H, Wang K, Lan X (2019) Aptamer oligonucleotides as potential therapeutics in hematologic diseases. Mini Rev Med Chem 19(10):788–795. https://doi.org/10.
2174/1389557517666171002160526
27. Group VISiONCT, Chakravarthy U, Adamis AP, Cunningham ET, Jr., Goldbaum M, Guyer
DR, Katz B, Patel M (2006) Year 2 efficacy results of 2 randomized controlled clinical trials
of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113(9):1508
e1501–1525. https://doi.org/10.1016/j.ophtha.2006.02.064
28. Feucht N, Matthias H, Lohmann CP, Maier M (2008) Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany. Clin Ophthalmol
2(2):253–259. https://doi.org/10.2147/opth.s2842
29. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC (2008)
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled
factor IXa inhibitor. J Thromb Aemost JTH 6(5):789–796. https://doi.org/10.1111/j.15387836.2008.02932.x
369
12. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R (2010) Applications of aptamers in
nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine 5(9):1435–
1445. https://doi.org/10.2217/nnm.10.115
13. Zou X, Wu J, Gu J, Shen L, Mao L (2019) Application of aptamers in virus detection and
antiviral therapy. Front Microbiology 10:1462. https://doi.org/10.3389/fmicb.2019.01462
14. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA
ligands to bacteriophage T4 DNA polymerase. Science 249(4968):505–510. https://doi.org/
10.1126/science.2200121
15. Ali MH, Elsherbiny ME, Emara M (2019) Updates on aptamer research. Int J Mol Sci 20(10).
https://doi.org/10.3390/ijms20102511
16. Yan J, Xiong H, Cai S, Wen N, He Q, Liu Y, Peng D, Liu Z (2019) Advances in aptamer
screening technologies. Talanta 200:124–144. https://doi.org/10.1016/j.talanta.2019.03.015
17. Wang T, Chen C, Larcher LM, Barrero RA, Veedu RN (2019) Three decades of nucleic acid
aptamer technologies: lessons learned, progress and opportunities on aptamer development.
Biotechnol Adv 37(1):28–50. https://doi.org/10.1016/j.biotechadv.2018.11.001
18. Zhang Y, Lai BS, Juhas M (2019) Recent advances in aptamer discovery and applications.
Molecules 24(5). https://doi.org/10.3390/molecules24050941
19. Bauer M, Strom M, Hammond DS, Shigdar S (2019) Anything you can do, i can do better:
can aptamers replace antibodies in clinical diagnostic applications? Molecules 24(23). https://
doi.org/10.3390/molecules24234377
20. Toh SY, Citartan M, Gopinath SC, Tang TH (2015) Aptamers as a replacement for antibodies
in enzyme-linked immunosorbent assay. Biosens Bioelectron 64:392–403. https://doi.org/10.
1016/j.bios.2014.09.026
21. Zamay TN, Zamay GS, Shnayder NA, Dmitrenko DV, Zamay SS, Yushchenko V, Kolovskaya
OS, Susevski V, Berezovski MV, Kichkailo AS (2020) Nucleic acid aptamers for molecular
therapy of epilepsy and blood-brain barrier damages. Mol Ther Nucl Acids 19:157–167.
https://doi.org/10.1016/j.omtn.2019.10.042
22. Yazdian-Robati R, Bayat P, Oroojalian F, Zargari M, Ramezani M, Taghdisi SM, Abnous K
(2019) Therapeutic applications of AS1411 aptamer, an update review. Int J Biol Macromol.
https://doi.org/10.1016/j.ijbiomac.2019.11.118
23. Panigaj M, Johnson MB, Ke W, McMillan J, Goncharova EA, Chandler M, Afonin KA (2019)
Aptamers as modular components of therapeutic nucleic acid nanotechnology. ACS Nano.
https://doi.org/10.1021/acsnano.9b06522
24. Nuzzo S, Roscigno G, Affinito A, Ingenito F, Quintavalle C, Condorelli G (2019) Potential
and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision
medicine in cancer. Cancers 11(10). https://doi.org/10.3390/cancers11101521
25. Maimaitiyiming Y, Hong F, Yang C, Naranmandura H (2019) Novel insights into the role of
aptamers in the fight against cancer. J Cancer Res Clin Oncol 145(4):797–810. https://doi.
org/10.1007/s00432-019-02882-7
26. Li W, Zhao M, Yan H, Wang K, Lan X (2019) Aptamer oligonucleotides as potential therapeutics in hematologic diseases. Mini Rev Med Chem 19(10):788–795. https://doi.org/10.
2174/1389557517666171002160526
27. Group VISiONCT, Chakravarthy U, Adamis AP, Cunningham ET, Jr., Goldbaum M, Guyer
DR, Katz B, Patel M (2006) Year 2 efficacy results of 2 randomized controlled clinical trials
of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113(9):1508
e1501–1525. https://doi.org/10.1016/j.ophtha.2006.02.064
28. Feucht N, Matthias H, Lohmann CP, Maier M (2008) Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany. Clin Ophthalmol
2(2):253–259. https://doi.org/10.2147/opth.s2842
29. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC (2008)
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled
factor IXa inhibitor. J Thromb Aemost JTH 6(5):789–796. https://doi.org/10.1111/j.15387836.2008.02932.x